Treating Triple-Negative Breast Cancer

Slideshow

This slide deck covers the treatment of triple-negative breast cancer, a heterogeneous disease made up of numerous subtypes, and includes clinical variables that can help with prognosis and guide in treatment choice.

Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; Ruth M. O'Regan, MD; and Anna Weiss, MD, presenting slides
More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.
Related Content
Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer.

Capivasertib Combo Does Not Meet OS End Points in Advanced TNBC

Russ Conroy
June 19th 2024
Article

Capivasertib's safety profile in the CAPItello-290 trial was comparable with prior reports of the agent in advanced triple-negative breast cancer.

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber, MD, MPH
November 15th 2017
Podcast

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Survival Outcomes Improve With TIL Presence in TNBC

Ariana Pelosci
April 16th 2024
Article

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Peter Schmid, MD
April 7th 2017
Podcast

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

Russ Conroy
February 13th 2024
Article

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC

Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC

Hayley Virgil
December 21st 2023
Article

Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.